Medical devices, healthcare technology and the business of care
510(k) clearance · K260917

cobas CT/NG for use on the cobas 5800/6800/8800 systems; cobas TV/MG for use on the cobas 5800/6800/8800 systems

Roche Molecular Systems, Inc. · Decision date Jul 8, 2026

FDA DECISIONK260917

What did the FDA decide?

FDA records K260917 as a 510(k) premarket notification, with a decision dated Jul 8, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Microbiology
Decision date
Jul 8, 2026

FDA source record

Regulatory record facts

Identifier
K260917
Regulatory pathway
510(k) premarket notification
Product code
QEP
Decision code
SESE
Decision date
Jul 8, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Nucleic Acid Detection System For Non-Viral Microorganism(S) Causing Sexually Transmitted Infections.

Product code
QEP
FDA device class
2

FDA decision timeline

  1. K260917 received

    Application receipt date recorded by FDA.

  2. K260917 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QEP

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.510(k) clearanceMay 15, 2026FDA
Roche Molecular Systems, Inc.510(k) clearanceMay 15, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular Systems, Inc.

Headquarters
Not reported
Brand website
roche.com
FDA applicant address
Pleasanton, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records